The Physiopathology Behind Valve Degeneration in TAVR

The degeneration of transcatheter biological valves clearly depends on time and starts with thrombus generation and subsequent histological changes resulting in valve failure (due to regurgitation, stenosis, or both).

La enfermedad vascular periférica se asocia a más eventos en el TAVIThrombus formation is the first change, observed early in computerized tomography (CT) scans after implantation. Most times it is completely asymptomatic, which leaves many of us wondering whether we should actually do something about this phenomenon.

 

This study provides more data and tells us that, perhaps, thrombus formation is just the beginning of a series of consecutive events over time such as endothelial hyperplasia, fibrosis, tissue remodeling, proteinase expression, and, ultimately, calcification.

 

This is the first study to investigate processes causing leaflet thickening and structural degeneration of transcatheter valves.


Read also: Bundle Branch Block and Need for Permanent Pacemaker, a Major Challenge after TAVR.


A few alarms went off with the first CT imaging studies showing thrombus formation and thickening. Based on those studies, this work provides histological details to better understand this phenomenon.

 

Researchers studied 23 explanted valves from 22 patients, from 0 to 2583 days after the procedure. Maximal leaflet thickness increased relative to implant duration (p = 0.027). Valves explanted after 2 years were thicker than those with shorter duration (p = 0.0027). All valves had adherent thrombi on both aortic and ventricular sides, which after 60 days combined with fibrosis and after 4 years, with calcification.

 

Early thrombus formation (<60 days after the procedure) occurred despite rapid endothelialization and was associated with an abnormal hyperplastic phenotype. Fibrosis was observed in 6 patients on both the aortic and the ventricular surfaces, and remodeled over time. All these changes were associated with matrix metalloproteinase-1 expression.


Read also: TAVR Is Feasible and Offers Good Outcomes in Patients with Cancer.


Five patients showed calcification, always associated with adherent thrombus and fibrosis.

 

Conclusion

Percutaneous valves degenerate over time. Such process seems to begin with thrombus formation and, after several evolution steps, results in calcification. Future investigations are needed to further understand these phenomena contributing to leaflet thickening and ulterior degeneration, and, above all, to try and prevent it, thus prolonging device duration. So far, the key seems to be taking measures during the earliest stage, the formation of adherent thrombi.

 

Original title: Transcatheter Aortic Heart Valves. Histological Analysis Providing Insight to Leaflet Thickening and Structural Valve Degeneration.

Reference: Stephanie L. Sellers et al. J Am Coll Cardiol Img 2019. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Su opinión nos interesa. Puede dejar su comentario, reflexión, pregunta o lo que desee aquí abajo. Será más que bienvenido.

More articles by this author

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...